Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Tenax Therapeutics (TENX) Enterprise Value (2016 - 2026)

Tenax Therapeutics' Enterprise Value history spans 8 years, with the latest figure at -$7.7 million for Q4 2017.

  • On a quarterly basis, Enterprise Value rose 41.82% to -$7.7 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$7.7 million, a 41.82% increase, with the full-year FY2017 number at -$7.7 million, up 41.82% from a year prior.
  • Enterprise Value hit -$7.7 million in Q4 2017 for Tenax Therapeutics, up from -$8.5 million in the prior quarter.
  • Over the last five years, Enterprise Value for TENX hit a ceiling of -$783528.0 in Q2 2013 and a floor of -$58.3 million in Q2 2014.
  • Historically, Enterprise Value has averaged -$11.3 million across 5 years, with a median of -$7.9 million in 2015.
  • Biggest five-year swings in Enterprise Value: plummeted 7343.33% in 2014 and later skyrocketed 86.41% in 2015.
  • Tracing TENX's Enterprise Value over 5 years: stood at -$783528.0 in 2013, then plummeted by 7343.33% to -$58.3 million in 2014, then soared by 65.38% to -$20.2 million in 2015, then soared by 34.22% to -$13.3 million in 2016, then skyrocketed by 41.82% to -$7.7 million in 2017.
  • Business Quant data shows Enterprise Value for TENX at -$7.7 million in Q4 2017, -$8.5 million in Q3 2017, and -$8.8 million in Q2 2017.